Immune Dysregulation in MDS: The Role of Cytokines and Immune Cells by D’Silva, Selma et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Immune Dysregulation in MDS: 
The Role of Cytokines and 
Immune Cells
Selma D’Silva, Sunil B. Rajadhyaksha  
and Meenakshi Singh
Abstract
Myelodysplastic syndrome (MDS) is a hematopoietic stem cell disorder affecting 
individuals over the age of 60 years. It is characterized by ineffective hematopoiesis 
and extensive apoptosis of hematopoietic cells. MDS patients are at a high risk of 
transforming in to acute myeloid leukemia. The main cause of apoptosis and escape 
from immune surveillance in MDS is immune dysregulation caused by a number of 
factors such as aberrant cytokine production and influence of various immune cells. 
In the past decade various pro-inflammatory cytokines and a number of immune 
cells such as Natural Killer cells, regulatory T cells, cytotoxic T cells, mesenchymal 
stem cells, myeloid derived suppressor cells and dendritic cells have been implicated 
in immune dysregulation leading to MDS pathogenesis. In this review we focus on 
the current data available on the role of these immune factors.
Keywords: myelodysplastic syndrome, cytokines, natural killer cells,  
dendritic cells, mesenchymal derived stem cells
1. Introduction
Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell 
disorders with ineffective hematopoiesis, cytopenias and risk of transformation 
to acute myeloid leukemia (AML). Incidence of MDS is higher in older individuals 
(>70 years of age) [1, 2]. The severity of MDS could range from indolent disease 
in which no blood transfusion is required, to borderline AML. An individual can 
get MDS either de novo, secondary to other myeloid disorders or MDS related to 
therapy. There are several point mutations associated with MDS [3–5]. Few of 
the individuals carrying these point mutations have a risk of developing MDS in 
the future but the factors involved in progression of the disease have not yet been 
identified [6]. MDS is a multifactorial disorder arising due to factors such as genetic 
alterations, epigenetic changes, gene transcription dysregulation and immune 
dysregulation [7]. This chapter is a review of the current data available indicating 
the role of immune cells in immune dysregulation related to MDS pathogenesis.
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2. Classification of MDS
In 1982, the French-American-British (FAB) classification was established for 
categorizing various MDS cases. According to this classification, all MDS patients 
were classified into one of the five groups based on the number of myeloblasts 
present in the bone marrow: refractory anemia, refractory anemia with ring sidero-
blasts, chronic myeloid leukemia, refractory anemia in excess of blasts (RAEB), and 
RAEB in transformation (RAEB-T) [8]. This was then later modified into the World 
Health Organization (WHO) classification which consists of the following groups: 
Refractory cytopenia with unilineage dysplasia (RCUD), Refractory anemia with 
ringed sideroblasts (RARS), Refractory anemia with multilineage dysplasia(RAMD), 
Refractory anemia with excess blasts-1 (RAEB-1), Refractory anemia with excess 
blasts-2 (RAEB-2), Unclassified myelodysplastic syndrome (MDS-U), MDS asso-
ciated with isolated deletion 5q, and Refractory cytopenia of childhood (RCC). 
Various prognostic scoring systems are used in clinical practice to predict overall 
survival and risk of transformation to AML in MDS patients. Currently, the 
International Prognostic Scoring System (IPSS) is used for risk stratification and 
treatment decision making. This system divides MDS patients into 4 different risk 
categories: low risk, intermediate-1 risk, intermediate-2 risk and high risk, based on 
the number of cytopenias, the percentage of blasts and cytogenetics [9].
3. Immune dysregulation in MDS
Immune cells are typically involved in immune surveillance, however, they also 
play a role in disease progression. Many studies have highlighted the role of dif-
ferent immune cells in immune dysregulation leading to pathogenesis of MDS and 
progression of disease to AML (Table 1). These factors could range from aberrant 
cytokine levels, increased T helper and cytotoxic cells, lower number of regulatory 
T cells, and dysfunctional Natural Killer (NK) cells among others.
In MDS there is an imbalance in cell production and apoptosis of aberrant 
cells. The main feature of MDS is high rate of apoptosis leading to cytopenia. The 
disturbed immune system leads to cytopenia by not only killing the tumor cells but 
also normal hematopoietic precursors. The immune dysregulation mechanisms vary 
between the low-risk and high-risk MDS patients, wherein, low risk patients show 
a high rate of apoptosis resulting from an immune system that is in an activated 
proinflammatory state, and in high risk patients there is increase in clonality of the 
tumor cells which escape immune surveillance resulting in a more immunosuppres-
sive environment [7].
Innate immune cells such as cytokines and NK cells and T cells of the adaptive 
immunity play a major role in immunosurveillance. Since, immunosurveillance 
maintains the homeostasis as well as removes the aberrant cells any error in the 
immune regulatory pathways can lead to cancer [31]. The major cause of escape of 
immune surveillance in MDS is dysregulation of the immune mechanisms which 
involves various immune cells (Figure 1).
3.1 Role of cytokines in immune dysregulation in MDS
Cytokines and chemokines are soluble low-molecular-weight proteins secreted 
by immune cells that mediate inflammatory responses and regulate hematopoiesis 
by modulating bone marrow microenvironment. These are essential for the viabil-
ity, proliferation and differentiation of hematopoietic stem cells. The lymphoid 
tissues host the effector lymphocytes in their nascent form. Upon stimulation by 
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chemokines released by the macrophages, the lymphocytes secrete  pro-inflammatory 
cytokines such as IL-2, IFN-gamma, IL-17 and TNF-alpha. Additionally, cytokines 
such as IL-10 and TGF-Beta are also secreted which down regulate the immune 
Sr. 
No.
Immune factor Levels Results References
1 TNF-α High Increased rate of apoptosis [10]
2 IL2 High Higher levels in advanced stage MDS as 
compared to early stage
[11]
3 IL6, GM-CSF High Higher levels in advanced stage MDS as 
compared to early stage
[12]
4 TNF-α High Lower overall survival and lower event 
free survival
[13]
5 TNF-α Low (<10 pg./ml) Better overall survival and better 
progression free survival
[14]
6 CD4
+ and CD8
+ Low Response to immunosuppressive therapy [15]
7 CD3
+ and CD8
+ Low frequent infections, lower overall survival 
and transformation into AML
[16]
8 CD8
+ T cells High Inhibition of hematopoiesis [17, 18]
9 CTLA-4 High Suppression of T cell activity, escape 
from immune surveillance, resistance to 
immunotherapy
[19]
10 CTL’s High Impairment of immune surveillance and 
disease progression
[20]
11 MDSC’s High Inefficient hematopoiesis [21]
12 MSC’s High Increased apoptosis, immunosuppression 
and reduced hematopoiesis
[22]
13 MSC’s High Poor potential for inhibition of DC 
differentiation and maturation in low-risk 
MDS patients
[10]
14 DC’s Abnormalities Escape of tumor cell from immune 
recognition, Higher rate of relapse after 
HSCT
[23]
15 IFN-γ producing 
NK Cells
Low Decreased cytolytic function leading to 
increased tumor load
[24]
16 CD56dimCD16+ NK 
cells
High Dysregulation of immune surveillance 
and ineffective hematopoiesis
[25]
17 Tregs Low Defective immune activation and 
decreased immune surveillance
[26, 27]
18 Tregs Low T cell cytotoxicity leading to increased 
apoptosis in low risk MDS
[28]
19 Tregs High Impaired antineoplastic immunity and 
immune suppression in High risk MDS
[15, 28, 29]
20 Th22 (IL22 
producing T cells)
High Increased apoptosis in high risk MDS 
patients
[30]
TNF-α: tumor necrosis factor-alpha; IL-2: interleukin-2, IL6: interleukin 6, GM-CSF: granulocyte macrophage 
colony-stimulating factor, CD4+: cluster of differentiation 4, CD8+: cluster of differentiation 8, CD3+: cluster of 
differentiation 3, CTLA-4: cytotoxic T-lymphocyte-associated antigen 4, CTL’s: cytotoxic T lymphocytes, MDSC’s: 
marrow derived stem cells, MSC’s: mesenchymal stem cells, DC’s: dendritic cells, IFN-γ: interferon gamma, NK: 
natural killer, CD56: cluster of differentiation 56, CD16: cluster of differentiation 16, Tregs: T regulatory cells.
Table 1. 
The role of various immune cells in MDS pathogenesis.
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response and contribute in healing the tissue involved. TGF-Beta is also an inducer 
of regulatory T cells (Tregs). Cytokines such as TNF-alpha have been associated with 
pathogenesis of high risk MDS, however, their prognostic value is unknown.
One of the causes of cytopenia in MDS is abnormal apoptosis. The increased 
expression of cytokines such as TNF-alpha, upregulates the expression of cell 
surface protein Fas receptor. This Fas receptor when bound to its cognate Fas ligand 
triggers apoptosis of the cell carrying the Fas receptor via the Fas associated death 
domain (FADD). Hence higher levels of TNF-alpha have been associated with rate 
of apoptosis in MDS patients [27].
Abnormal levels of cytokines, chemokines and growth factors in MDS patients 
have been reported by various researchers [32–34]. The levels of pro-inflammatory 
cytokines such as TNF-alpha, IFN-gamma, TGF-Beta, IL6, IL8, and granulocyte-
CSF have been shown to be increased in MDS patients, highlighting the role of these 
immune cells in immune dysregulation related to MDS [33, 35–39]. Kornblau et al. 
[40] reported that MDS patients have lower levels of pleiotropic cytokines IL10 
and IL4 as compared to healthy controls. Zoumbos et al. [11] have reported higher 
serum IL2 levels in patients with advanced MDS as compared to early stage patients. 
Similarly, higher serum IL6 and GM-CSF levels have been reported in patients with 
Figure 1. 
The role of various immune cells in MDS pathogenesis. A. The abnormal proliferation of MDS hematopoietic 
cells. The increased release of various pro-inflammatory cytokines directs the recruitment of MDSC’s at the 
tumor site. These kill the erythroid precursor cells and also lead to suppression of CTL activity. Lower number 
of Tregs enables the tumor cells to escape immune surveillance and leads to accumulation of uncontrolled 
proliferation of MDS cells. B. The decrease in normal hematopoiesis. The release of cytokines also leads to 
increase in the number of natural killer and cytotoxic T cells, which induces apoptosis in hematopoietic stem 
cells. This in turn results in lower number of functional bone marrow progenitor cells. TNF-α: tumor necrosis 
factor-alpha, IL2: interleukin-2, IL6: interleukin-6, MDSC: marrow derived stem cells, CTL: cytotoxic T cells, 
Tregs: regulatory T cells, MDS: mesenchymal stem cells, HPC: hematopoietic cells, NK: natural killer.
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advanced MDS [12]. Verhoef et al. [34] have also reported higher levels of IL-3, IL-6 
and G-CSF in patients with MDS as compared to controls.
Aberrant cytokine levels have also been associated with MDS clinical outcomes. 
Tsimberidou et al. [13] have associated higher levels of leukocytes and lower levels 
of hemoglobin with lower overall survival and event free survival in high-risk 
MDS patients having higher TNF-alpha levels. Meyers et al. [41] have associated 
higher levels of TNF-alpha, IL-6, IL-1R with fatigue in MDS patients. Low TNF-
alpha (<10 pg./ml) have been associated with better overall survival and better 
progression free survival [14]. Pardanani et al. [42] suggested the levels of IL6, IL7 
and CXCL10 to be an independent prognostic factor for overall survival, wherein, 
patients with normal levels of these cytokines show better overall survival as 
compared to those with elevated levels of at least 1.
Lopes et al. [43] reported difference in cytokine profiles between low and high 
risk MDS cases. Also an inverse relation between IL10 and CD8
+ T cells has been 
reported and IL10 expression is much higher in patients suffering from MDS. When 
comparing the MDS according to the risk, patients in the low risk group show 
elevated levels of type I cytokines such as IL-1Beta, IL7, IL8 and IL12, whereas 
high-risk MDS patients show elevated levels of inhibitory factors such as IL10 and 
sIL2 [13, 14]. Since low-risk MDS is associated with higher apoptotic rates, the levels 
of cytokines such as TNF-alpha, IFN-gamma and IL-6 are higher in these patients as 
compared to high-risk MDS patients [35]. High risk MDS is associated with escape 
of tumor clones from immune recognition and hence serum of these patients have 
higher amounts of immunosuppressive cytokines like IL10 [44]. IFN-gamma and 
IL-6 are involved in apoptosis induction in BM. Hence, when they are present in 
higher levels, it will result in a low risk MDS [27, 32].
4. Role of immune cells
4.1 Helper and cytotoxic T cells
Cytotoxic T cells (CTLs) are cells that are capable of killing cancer cells and 
abnormal cells. Most of these cells have a T cell receptor (TCR) that recognizes 
specific antigens, hence, stimulating an immune response. Functionally stable TCRs 
are associated with both CD4
+ and CD8
+ glycoproteins. CD4
+ glycoproteins are found 
on cells such as dendritic cells (DC), T helper cells, etc. and are involved in commu-
nicating with antigen presenting cells (APCs). The CD8
+ glycoprotein is present in 
various cytotoxic cells such as CTL, NK cells etc. Function of CD8
+ glycoprotein is to 
recognize and destroy foreign/infectious particles. Only when the TCR is associated 
with CD8
+ glycoprotein can it bind to the specific antigens and enable presentation 
and destruction of these foreign antigens [45, 46].
Growth of both malignant and non-malignant cells in MDS is inhibited by CD8
+ 
T cells that target MHC class I molecules on the hematopoietic precursors. This 
response forms part of the immune surveillance. Majority of MDS patients have 
peripheral blood lymphopenia, which results in reduction of CD4
+ and CD8
+ cell, 
leading to an inverted CD4/CD8 ratio in these patients. In younger patients there is a 
decrease in both naïve CD4
+ and CD8
+ T cells which is also correlated with response 
to immunosuppressive treatments [15].
The distribution of CD8
+ T cells differs between low and high risk MDS patients. 
Low risk MDS patients usually show downregulated Tregs and upregulated CD8
+  
T cells, whereas, high risk MDS patients have upregulated Tregs and downregulated 
CD8
+ T cells and NK cells. Symeonidis et al. [16] have reported association of CD3
+ 
and CD8
+ lymphopenia in MDS patients with frequent infections, lower overall 
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survival and transformation into AML. Smith et al. [17] demonstrated inhibition 
of hematopoiesis by CD8
+ T cells. This inhibition due to type-I polarization of CD4
+ 
and CD8
+ T cells was also confirmed by Wu et al. in 2008 [18].
Recently, a few epitopes on CD8
+ T cells such as Wilms tumor 1 protein (WT1), 
MHC Class I etc., have been implicated in activation of the CD8
+ T cells. Sloand et al. 
[47] reported that in MDS patients with trisomy 8, WT1 is highly overexpressed on 
CD34
+ T cells making these patients more responsive to immunosuppressive thera-
pies. However, these immunosuppressive therapies hinder tumor surveillance by  
T cells resulting in disease progression.
Further, molecules such as programmed death 1 (PD1), its ligand PD1L, and  
T cell associated antigen CTLA-4 suppress T cell activity leading to escape of tumor 
cells from immune surveillance and resistance to immunotherapy [19]. Sand et al. 
[20] have reported a higher number of CTL’s in high-risk MDS patients, however, 
these CTL’s have a lower TCR mediated cytotoxicity, which results in impairment of 
immune surveillance and leads to disease progression.
A Japanese study revealed lower marrow T cells in MDS-RAEB patients and low 
CD4
+CD45RA+ naïve cells in MDS patients indicating impaired immune surveillance 
and expansion of the tumor clone [48]. Hamdi et al. [49] reported higher Th1/
Th2 ratios in patients with lower risk prognostic score. Li et al. [50] have reported 
higher T cell count in low-risk MDS patients as compared to high-risk patients and 
controls.
These studies highlight the role of abnormal helper and cytotoxic T cells in 
autoimmunity towards hematopoietic progenitors.
4.2 Myeloid derived suppressor cells (MDSC’s)
Myeloid derived suppressor cells (MDSC’s) are cells belonging to the innate 
immunity involved in suppression of the immune system. These cells express CD33 
immune receptor [51]. They are generally in few numbers in healthy individuals but 
increase in response to stress stimuli. They have been reported in higher frequencies 
in various cancers.
MDSC’s are one of the cells that inhibit anti-tumor immunity. These can be 
differentiated based on the surface markers as monocytic (MO-MDSC) and 
granulocytic (PMN-MSDC). The surface markers on monocytic MDSC’s are 
CD11b+CD14+CD15−CD33+ and HLA-DRlow, whereas, those on granulocytic 
MDSC’s are CD11b+CD14−CD15+CD33+ and HLA-DRlow/−. MDSC’s are generally 
induced by the pro-inflammatory nature of the tumor cells. Their function is to 
inhibit both adaptive as well as the innate immune system by either cell–cell con-
tact or by releasing cytokines, which results in the inhibition of T cell prolifera-
tion and activation, induction of Tregs and NK cell impairment. MDSC’s are also 
involved in inhibiting T cells to settle in the lymph nodes and inflammation sites. 
MDSC’s derived from monocytes and granulocytes support tumor by releasing 
growth factors.
There is sparing data available regarding the role of MDSC in MDS. The increase 
in MDSC’s in MDS patient results in suppression of normal hematopoiesis and leads 
to progression of the disease. Chen et al. [21], reported an association of inef-
ficient hematopoiesis with increased MDSC’s in the bone marrow of patients with 
MDS. Graft versus host disease (GvHD) is the number one cause of morbidity and 
mortality following allogeneic hematopoietic stem cell transplantation. Low levels 
of MO-MDSC’s have been reported in association with onset of aGvHD [52]. The 
levels of both MO-MDSCs and PMN-MDSCs are increased in the peripheral blood 
soon after transplant and are reported to lower the risk of acute GvHD (aGvHD) as 
well as response to steroid therapy [53].
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Lechner et al. [54], reported the role of various cytokines in the development of 
MDSC’s. In MDS there are irregular levels of cytokines which indicates that targeting 
the cytokine levels can lead to loss of immunosuppression by the MDSC’s. Jiang et al. 
[55], reported increased levels of circulating MDSC’s in MDS patients. The imma-
ture myeloid cells induce secretion of cytokines such as IL-10 and TGF-Beta which 
increase the levels of MDSC’s.
4.3 Mesenchymal stem cells
MSC’s are self-renewing cells with the ability to differentiate into a number of 
cells such as adipocytes, and chondrocytes. The main role of MSC’s is maintaining 
normal hematopoiesis, however, they are also implicated in MDS pathogenesis. 
The role of MSC’s in MDS is different in low risk and high-risk patients. In high risk 
patients MSC’s induce apoptosis and suppress the immune system by secreting vari-
ous cytokines like TGF-B, whereas, in low risk patients they reduce the efficiency 
for inhibiting DC differentiation. Since MSC’s have an immunomodulatory role, 
they have been investigated for their role in MDS disease progression. However, 
most of the studies have reported contradictory results and a consensus on the 
involvement of MSC’s in MDS is not yet sought.
Han et al. [56] have demonstrated MSC’s with normal morphology and pheno-
type, but with deficient immunomodulatory function that could not inhibit in vitro 
T cell activation and proliferation. Klaus et al. [57], did not find any difference in 
the differentiation potential and immunosuppressive potential of MSC’s in MDS 
patients and controls. In high-risk MDS patients, Zhao et al. [22] reported MSC’s 
with an increase in apoptosis, immunosuppressive rate and reduced hematopoiesis, 
whereas, Wang et al. [10] reported MSC’s with poor potential for inhibition of DC 
differentiation and maturation in low-risk MDS patients.
4.4 Dendritic cells
The site of origin of DC’s is the bone marrow. There are four different types of 
dendritic cells present in the peripheral blood: plasmacytoid DCs (pDCs), two types 
of myeloid DCs and slan DC’s. The main function of DC’s is pathogen and tumor 
recognition and antigen presentation [58, 59]. Hence, any defect in DC’s could mean 
that the tumor cells will escape immune recognition [28, 29]. DC’s upregulate and 
activate co-receptors on T cells. In MDS patients the ability of DC’s to activate T cells 
is much lower as compared to healthy controls [60]. Ma et al. [61], reported simi-
larities in cytogenetic abnormalities in DC’s of MDS patients and in their malignant 
clones indicating that these abnormalities belonged to the malignant clone.
DC’s are equipped with Toll-like receptors and C-type lectin receptors which 
help in recognition of pathogens. DC’s are usually in a nascent state and upon con-
tact with potential pathogens they mature. During maturation there are morpho-
logical changes due to which the function of DC’s changes from pathogen capturing 
to cytokine secretion and antigen presentation. The processed antigens on MHC’s 
are presented by DC’s to naïve T cells which then elicit an immune response.
Various researchers have reported aberrant immune response by DC’s in dif-
ferent cancer types [62–66]. This defect could be in the frequency of DC’s, matu-
ration, cytokine secretion profile, and ability to induce T cell proliferation [7]. 
Abnormalities and defects in number of dendritic cells lead to escape of tumor cell 
from immune recognition, hence, resulting in higher rate of relapse after allogeneic 
HSCT [23]. The number and frequency of DC’s in the peripheral blood of MDS 
cases is much reduced as compared to healthy individuals [60, 61, 67]. Further their 
capability to stimulate T cells is also reduced due to lower surface expression of 
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molecules such as CD54, CD80 and CD86 [60]. Ma et al. [68] have reported lower 
IL12 secretion and higher IL10 secretion in DC’s from MDS patients. Saft et al. 
[23] reported lower myeloid and plasmacytoid precursor DC’s in high-risk MDS as 
compared to low-risk MDS patients.
4.5 Natural killer cells
Natural Killer cells (NK) play an important role in innate immunity. NK cells 
secrete cytokines and play an important role in host defense [69]. Their main role 
is to kill non-self cells, i.e., cells that lack self-major histocompatibility complex 
(MHC). NK cell cytotoxicity can either be activated or inhibited based on the sum 
of the activating and inhibitory receptors present on their surface. The inhibitory 
receptors could either be Killer immunoglobulin like receptors (KIR) or CD94/
NKG2A dimer which protect self-cells from NK cell lysis by binding to their cognate 
MHC Class I ligands [70], whereas, the activating receptors are the natural cyto-
toxic receptors (NCRs), namely, NKp46, NKp44, NKp30 and NKG2D [69, 71].
The role of NK cells in immune dysregulation in MDS results from reduction 
in total number or functional NK cells leading to defects in immune surveillance 
and hence disease progression. Since NK cells eliminate the aberrant cells from the 
system, deficiency of NK cell functionality has been associated with poor prognosis 
in MDS, hence, in older patients, where in the NK cell activity is already low due to 
aging, the NK cell activity decreases further.
Various reports have measured NK cells in MDS patients [72–74]. Epling-
Burnette et al., reported 2 types of NK cells based in their cytotoxicity: low function 
NK cells which have been associated with high-risk MDS, and normal function NK 
cells. Furthermore, they also reported defects in number of activating NK receptors 
such as NKG2D leading to progression of disease. They observed reduced NK cell 
cytolytic activity in MDS patients as compared to healthy donors. The activating 
receptors NKp30 and NKG2D was downregulated in these patients [74].
Fujii et al. [24], reported deficiency of IFN-gamma producing NK T cells in 
blood and marrow of MDS patients. This led to decreased cytolytic function leading 
to tumor load. Zhang et al. [25], report lower expression of CD3−CD56+CD16+ NK 
cells in MDS patients as compared to healthy individuals. CD16+ NK cells play an 
important role in tumor surveillance, and hence decreased count of these cells cor-
relate with the tumor cell load in MDS patients [75, 76].
CD56+ is a marker for NK cells that produce high levels of cytokines. Circulating 
NK cells usually exhibit CD56dim which produce lower amounts of cytokines as 
compared to CD56bright NK cells. Hence, CD56bright are known to have a more immu-
nomodulatory role as compared to CD56dim which are mostly cytotoxic in nature 
[77]. In patients with MDS, there is a higher prevalence of CD56dimCD16+ cells as 
compared to healthy controls which results in dysregulation of immune surveillance 
and ineffective hematopoiesis [25]. Hejazi et al. [72] conducted a study on 75 MDS 
patients, wherein it was observed that majority of the patients in the high risk group 
had a NK Cell deficiency, moreover, in another group, it was observed that although 
NK cells were present, they were non-functional. CD56dim NK cells were predomi-
nantly present which result in reduction of cytotoxicity.
4.6 Regulatory T cells
Tregs are T helper cells that are involved in immune tolerance and modulation 
of immune reactions. Regulatory T cells (Tregs) cells are CD4+CD25highFOXP3+ or 
CD4+CD25highCD127low. Tregs carry out immune tolerance as well as modulation of 
immune response and are the important for immune surveillance [27] by secreting IL10 
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and TGF-Beta which are immunosuppressive cytokines [78]. Any impairment in Tregs 
results in defective immune activation and decreased immune surveillance against the 
tumor cells [26]. Lower numbers of functional Tregs result in autoimmunity.
The exact role of Tregs in MDS progression is not very clear. However, variation 
in number of Tregs has been reported to be associated with disease progression, risk 
of transformation to AML and overall survival in MDS patients [29, 31, 49, 79].  
The very first study for the involvement of Tregs in MDS was demonstrated by 
Kordasti et al. [29], wherein, an association between increased CD4
+ Tregs and 
disease progression was shown. Low number of Tregs in bone marrow have been 
linked to increased CD8
+ T cells and the recruitment of Th17 proinflammatory cells 
[44, 80]. The number of Tregs differs based on the disease stage. In low-risk MDS, 
lower numbers of Tregs or impaired Tregs have been reported in association with 
T cell cytotoxicity leading to increased apoptosis, whereas, higher number of Tregs 
are seen in high-risk MDS patients and are associated with impaired antineoplastic 
immunity and immune suppression [15, 28, 29].
Costantini et al. [81] conducted a study to investigate the effect of 5-azacytidine 
on Tregs functionality in intermediate/high risk MDS patients. Following treat-
ment, lower numbers and Tregs with lower suppressive function were observed 
in these patients. Alfinito et al. [80] reported an inverse relationship between 
levels of Tregs and the degree of dyserythropoiesis. Hamdi et al. [49], reported an 
inverse ratio between Treg and CD8
+ frequencies in MDS patients. Low risk MDS 
patients have higher number of Th17 cells which is inversely correlated with Tregs 
numbers. Hence in these patients the Th17/Tregs ratio is found to be increased [44]. 
Shao et al. [30] have shown increased number of Th22 (IL22 producing T cells) in 
high-risk MDS patients. This increased number of Th22 is correlated with release of 
pro-inflammatory cytokines leading to increased apoptosis.
5. Immunosuppressive therapy
The most curative treatment for MDS is allogeneic hematopoietic stem cell ther-
apy; however, since MDS develops mostly later in life, most patients are rendered 
ineligible for transplantation and supportive care is their only option for treatment. 
As previously discussed, many researchers have shown the involvement of immune 
cells in the pathogenesis of MDS and hence, immunosuppression involving target-
ing these cells has evolved as one of the treatment modalities.
Molldrem et al. and Jonasova et al. [82, 83] were the first to report the use of 
immunosuppressive therapy (IST) in MDS with Antithymoglobulin (ATG) in 1997 
and Cyclosporin (CsA) in 1998 respectively. Jonasova et al. [83] reported positive 
response in MDS-RA patients treated with CsA. On the contrary, another study 
showed no advantage to CsA and also reported CsA related renal toxicity [84]. CsA 
acts by blocking IL-2 production which leads to inhibition of expansion of CTLs 
and suppression of cytokines like TNF-α which are involved in apoptosis [85]. ATG 
has a role in depleting T cells and restoring normal hematopoiesis [86]. It acts by 
interfering with the normal function of DC’s and hence inhibiting the interaction 
between the T cell and the antigen presenting cell. Moreover, ATG restores normal 
hematopoiesis by diminishing cytokine release by activated T cells [87].
Since reduced number of Tregs are associated with disease progression in low-
risk MDS, introduction of ex-vivo expanded Tregs is a potential targeted therapy 
in such patients. Not only the number but also the function of Tregs is important, 
hence, it is absolutely necessary to be sure that the ex-vivo expanded Tregs popula-
tion do not have non-regulatory effector cells. Functional Tregs can be also be 
induced by vaccination using tolerizing DC’s [88].
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6. Conclusions
It is now well known that genetic, epigenetic and aberrant immune factors play 
a major role in the pathogenesis of MDS, making it one of the most challenging 
disorders to design therapies for. Leaving aside the MDS patients in whom the 
major factor is genetic mutations, there is a group of patients in whom immune 
cells play a major role in the disease progression. In these patients, immunosup-
pressive therapies (IST) form part of the major treatment strategy. It is known that 
there is improved marrow function and increased survival in patients undergoing 
IST. However, identifying patients that will respond favorably is a challenge. Some 
targeted therapies involve introducing tolerogenic DC’s and expansion of Tregs. 
The therapeutic approach becomes more difficult because of the difference in the 
immune environment that exists between low-risk and high-risk MDS cases. For 
this the exact immune mechanisms involved and the specific immune cells respon-
sible for the pathogenesis in the particular group of patients need to be identified in 
order to establish targeted therapies in the future.
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